Concizumab (lub npe lag luam, Alhemo), ib qho tshuaj tiv thaiv monoclonal tau pom zoo los ntawm FDA ntawm 20 Lub Kaum Ob Hlis 2024 rau kev tiv thaiv los ntshav hauv cov neeg mob hemophilia A nrog yam VIII inhibitors lossis hemophilia B nrog yam IX inhibitors. Nws tau txais kev pom zoo los ntawm European Medicines Agency (EMA) ob peb hnub dhau los ntawm 16 Lub Kaum Ob Hlis 2024 rau tib cov lus qhia.
Qee cov neeg mob haemophilia ntawm "cov tshuaj tiv thaiv kab mob ntshav" rau kev kho lawv cov kev mob los ntshav tsim cov tshuaj tiv thaiv (tawm tsam cov tshuaj tiv thaiv kab mob). Cov tshuaj tiv thaiv tau tsim inhibit qhov kev ua ntawm "cov tshuaj tiv thaiv kab mob" ua rau lawv tsis zoo. Tus mob no yog tam sim no kho los ntawm inducing lub cev tiv thaiv kab mob los ntawm kev txhaj tshuaj txhua hnub ntawm clotting yam. Kev pom zoo ntawm Concizumab (Alhemo) muab cov neeg mob zoo li no nrog lwm txoj kev kho mob.
Concizumab yog siv txhua hnub raws li kev txhaj tshuaj subcutaneous.
Kev pom zoo ntawm Alhemo yog ua raws li kev soj ntsuam ntawm nws txoj kev nyab xeeb thiab kev ua tau zoo hauv ntau lub teb chaws, ntau lub chaw, qhib-daim ntawv lo, theem 3 kev sim tshuaj. Hauv kev sim, tus nqi txhua xyoo los ntshav (ABR) raug txo los ntawm 86% rau pawg kho mob Alhemo piv rau pawg tsis muaj kev tiv thaiv.
Kev mob ntshav los ntshav hauv haemophilia yog tshwm sim los ntawm qhov tsis txaus ntawm cov ntshav txhaws. Haemophilia A yog tshwm sim los ntawm qhov tsis txaus ntawm cov ntshav txhaws VIII, thaum haemophilia B yog vim tsis muaj qib IX. Tsis muaj qhov ua tau zoo XI yog lub luag haujlwm rau haemophilia C. Cov xwm txheej no tau kho los ntawm kev ua lag luam npaj cov khoom lag luam los yog cov khoom tsis yog khoom raws li kev hloov pauv ntawm qhov ploj lawm.
Octocog alfa (Advate), uas yog 'genetically engineered siv DNA technology' version of clotting factor VIII, feem ntau yog siv rau kev tiv thaiv raws li qhov xav tau kev kho mob ntawm haemophilia A. Rau haemophilia B, nonacog alfa (BeneFix), uas. yog ib qho kev tsim qauv ntawm cov khoom siv IX feem ntau siv.
Hympavzi (marstacimab-hncq), tib neeg monoclonal antibody tsom rau "cov ntaub so ntswg pathway inhibitor" tsis ntev los no tau pom zoo ua cov tshuaj tshiab rau kev tiv thaiv los ntshav rau cov neeg muaj hemophilia A lossis hemophilia B.
***
References:
- FDA pom zoo siv tshuaj los tiv thaiv lossis txo qhov zaus los ntshav rau cov neeg mob hemophilia A nrog inhibitors lossis hemophilia B nrog inhibitors. Tshaj tawm 20 Kaum Ob Hlis 2024. Muaj nyob ntawm https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-prevent-or-reduce-frequency-bleeding-episodes-patients-hemophilia-inhibitors-or
- EMA. Alhemo - Concizumab. Muaj https://www.ema.europa.eu/en/medicines/human/EPAR/alhemo thiab https://ec.europa.eu/health/documents/community-register/html/h1881.htm
- NHS. Kev kho mob Hemophilia. Muaj nyob ntawm https://www.nhs.uk/conditions/haemophilia/treatment/
- CDC. Kev kho mob Hemophilia. Muaj nyob ntawm https://www.cdc.gov/hemophilia/treatment/index.html
Tshooj cai
- Hympavzi (marstacimab): Kev Kho Tshiab rau Hemophilia. Kev tshawb fawb European. Tshaj tawm 12 Lub Kaum Hli 2024. Muaj nyob ntawm https://www.scientificeuropean.co.uk/medicine/hympavzi-marstacimab-new-treatment-for-hemophilia/
***
, a monoclonal antibody was approved by the FDA on 20 December 2024 for prevention of bleeding episodes in patients with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors. It had received approval by the European Medicines Agency (EMA) few days ago on 16 December 2024 for the same indications.){kind=link}